

List of Publications

(<http://www.ncbi.nlm.nih.gov/pubmed?term=kamal-ma>)

1. Y Tan, MA Kamal, Z-Z Wang, W Xiao, JP Seale, X Qu (2010) Chinese herbal extracts (SK0506) as a potential candidate for the therapy of metabolic syndrome. Clin. Sci. (in press).
2. M.A. Kamal, P. Klein (2010) Determination of sugars in Honey by Liquid Chromatography. SJBS (in press; <http://dx.doi.org/10.1016/j.sjbs.2010.09.003>).
3. M.A. Kamal, M. Reale & A.A. Al-Jafari (2010) Multiple approaches to analyze the data for rat brain acetylcholinesterase inhibition by cyclophosphamide. Neurochem. Res.35(10):1501-1509 (<http://www.springerlink.com/openurl.asp?genre=article&id=doi:10.1007/s11064-010-0199-y>).
4. M.A. Kamal, P. Klein (2010) Estimation of BTEX in Groundwater by Using Gas Chromatography-Mass Spectrometry. SJBS. 17(3): 205-208.
5. M. Reale, N.H. Greig & M.A., Kamal (2009) Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's disease. Mini Rev. Med. Chem. (IF 3.132), 9(10): 1229-1241.
6. M.A. Kamal, Y. Tan, J.P. Seale & X Qu (2009) Targeting BuChE-Inflammatory Pathway by SK0506 to Manage Type 2 Diabetes and Alzheimer Disease. Neurochem. Res. 34(12), 2163-2169, (<http://www.springerlink.com/openurl.asp?genre=article&id=doi:10.1007/s11064-009-0011-z>).
7. M.A. Kamal, N.H. Greig and M. Reale (2009) Anti-Inflammatory Properties of Acetylcholinesterase Inhibitors Administered in Alzheimer's disease. Anti-Inflamm. Anti-Allergy Agents in Med Chem. 8(1): (min-review), 85-100 (<http://www.bentham.org/cmcaiaa/CurrentIssue.htm#9>).
8. MA Kamal, X Qu, Q-s Yu, D Tweedie, HW Holloway, Y Li, Y Tan, NH Greig (2008) Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. J. Neural Trans. 115(6): 889-898.
9. M.A. Kamal, P. Klein, W. Luo, Y. Li, H.W. Holloway, D. Tweedie, N.H. Greig (2008) Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine. Neurochem. Res. 33(5): 745-753.
10. Greig NH, Utsuki T, Yu QS, Kamal MA, Holloway HW, Perry T, Tweedie D, Li Y, Giordano T, Alley GM, Chen DM, Rogers JT, Sambamurti K, and Lahiri DK (2008) Dissociation between the potent b-amyloid protein pathway inhibition and cholinergic actions of the Alzheimer drug candidates phenserine and cymserine. "In: Advances in Alzheimer's and Parkinson's Disease: Insights, Progress, and Perspectives, (Eds. A. Fisher, M. Memo, F. Stocchi, and I.Hanin), Springer Science + Business Media, USA, 445-462.

11. M.A. Kamal & P Klein (2007) Estimation of Fatty Acids in Oils by Gas Capillary Chromatography. *SJBS*. 14 (1), 17-20.
12. M.A. Kamal, Q-S. Yu, H.W. Holloway, D. Tweedie, P. Klein, N.H. Greig (2006) Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. *J. Alz. Disease*, 10(1), 43-51.
13. D. Tweedie, A. Brossi, DeM. Chen, Y-W. Ge, J. Bailey, Q-S. Yu, M.A. Kamal, K. Sambamurti, D.K. Lahiri, N.H. Greig (2006) Neurine, an acetylcholine autolysis product, elevates secreted amyloid β -precursor protein and amyloid β peptide levels, and lowers neuronal cell viability in culture: a role in Alzheimer's disease? *J. Alz. Disease*, 10(1), 9-16.
14. M.A. Kamal, A.A. Al-Jafari, Qian-sheng, Yu & N.H. Greig (2006) Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine. *Biochem. Biophys. Acta* 1760, 200-206.
15. M.A. Kamal (2005) Interaction of antifolates with enzymes of the de novo purine pathway in human CCRF-CEM leukaemia cells: Monitored using HPLC linked with UV and radioactive detectors. *Em. Med. J.* **23**(2), 155-164.
16. M.A. Kamal, A.A. Al-Jafari & N.H. Greig (2005) Interaction of new anti-Alzheimer's disease agents with cholinesterase. *J. Neurochem.* **94**(s2), 168.
17. M.A. Kamal & R.I. Christopherson (2004) Accumulation of 5-phosphoribosyl-1-pyrophosphate in human CCRF-CEM leukaemia cells treated with antifolates. *Int. J. Biochem. Cell Biol.*, **36**, 545-551.
18. M.A. Kamal, N.H. Greig & A.A. Al-Jafari (2002) A new, simple and economical approach to analyse the inhibition kinetics of acetylcholinesterase using tolserine. *Em. Med. J.*, **20**(3), 333-337.
19. M.A. Kamal & A.A. Al-Jafari (2001) A graphical kinetic analysis model for the inhibition of acetylcholinesterase by anti-Alzheimer's drug, tacrine. *S. J. Biol. Sci.*; **8**(2), 113-122.
20. M.A. Kamal, N.H. Greig, A.S. Alhomida & A.A. Al-Jafari. Kinetics of human acetylcholinesterase inhibition by novel experimental Alzheimer therapeutic agent, tolserine. *Biochem. Pharmacol.*, **60** (4), 561-570, 2000.
21. S. Alhomida, A.S. Al-Rajhi, M.A. Kamal & A.A. Al-Jafari. Kinetic analysis of the effect of Cognex (tacrine) on human retinal acetylcholinesterase activity. *Toxicology*, **147**, 33-39, 2000.
22. M.A. Kamal, A.S. Alhomida, A.A. Al-Rajhi & A.A. Al-Jafari. Thermodynamic analysis of human retinal acetylcholinesterase inhibition using an anti-Alzheimer's drug, tacrine, through the development of a dual substrate and temperature model. *Proc. Natl. Sci. Coun., Life Sci. (B)*, **24** (3), 108-115, 2000.

23. M.A. Kamal, F.H. Nasim & A.A. Al-Jafari. Graphical kinetic approach for estimation of various new constants for inhibition of acetylcholinesterase by cisplatin. *Pak. J. Biol. Sci.*, **3** (6), 920-923, 2000.
24. M.A. Kamal & A.A. Al-Jafari. Dual substrate model for novel approach toward kinetic study of acetylcholinesterase inhibition by diazinon. *J. Enz. Inhib.*, **15/2**, 201-213, 2000.
25. M.A. Kamal & A.A. Al-Jafari. Mode of inhibition of bovine retinal acetylcholinesterase by gallamine triethiodide in vitro. *Pak. J. Biol. Sci.*, **3** (5), 767-771, 2000.
26. A.A. Al-Jafari, M.A. Kamal, A.S. Alhomida and N.H. Greig. Kinetics of rat brain acetylcholinesterase inhibition by two experimental Alzheimer's disease drugs, phenserine and tolserine. *J. Biochem. Mol. Biol. Biophys.*, **4**, 323-335, 2000.
27. M.A. Kamal. Effect of some anti-cancer drugs on human erythrocyte acetylcholinesterase (topic of **Ph.D. thesis**), Department of Chemistry, Islamia University, Bahawalpur, Pakistan, 1999.
28. M.A. Kamal, F.H. Nasim & A.A. Al-Jafari. Human erythrocyte acetylcholinesterase inhibition by cis-diamminediaquaplatinum (II): a novel kinetic approach. *Cancer Lett.*, **138**, 115-119, 1999.
29. M.A. Kamal & A.A. Al-Jafari. Kinetic constants for the inhibition of camel retinal acetylcholinesterase by the carbamate insecticide lannate. *J. Biochem. Mol. Toxicol.*, **13** (1), 41-46, 1999.
30. M.A. Kamal & A.A. Al-Jafari. Comparative kinetics of the inhibition of human plasma butyrylcholinesterase by tacrine, estimated by new and classical methods. *J. Neurochem.*, **73**, S50-S50, 1999.
31. A.A. Al-Jafari, M.A. Kamal, N.H. Greig, A.S. Alhomida & E. Perry. Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: Phenserine. *Biochem. Biophys. Res. Comm.*, **248** (1), 180-185, 1998.
32. A.A. Al-Jafari, M.A. Kamal & A.S. Alhomida. On the inhibition of camel retina acetylcholinesterase activity by cycloheximide in vitro. *Cell. Biol. Toxicol.*, **14**(3), 167-174, 1998.
33. A.A. Al-Jafari, F. Al-Khwyter & M.A. Kamal. Kinetics of the inhibition of acetylcholinesterase in camel retina by cisplatin. *Cancer. Lett.*, **128**, 79-86, 1998.
34. A.A. Al-Jafari, M.A. Kamal & A.S. Alhomida. Sensitivity of bovine retinal acetylcholinesterase (EC 3.1.1.7) toward tacrine: Kinetic characterization. *J. Biochem. Mol. Toxicol.*, **12**(4), 245-251, 1998.
35. M.A. Kamal. Dual temperature model for the estimation of energetic parameters for

- acetylcholinesterase inhibition by cyclophosphamide. *Biochem. Mol. Biol. Int.*, **43** (3), 571-581, 1997.
36. A.A. Al-Jafari, M.A. Kamal, and A.S. Alhomida. Thermodynamic investigation of camel retina acetylcholinesterase inhibition by cyclophosphamide. *J. Enzyme Inhibition*, **11**, 275-283, 1997.
 37. M. A. Kamal. Effect of sevin on kinetic parameters of camel retina acetylcholinesterase. *Biochem. Mol. Biol. Int.*, **42** (2), 235-246, 1997.
 38. A.S. Alhomida, M.A. Kamal & A.A. Al-Jafari. Evaluation of the nature of camel retinal acetylcholinesterase inhibition by hexamethonium. *J. Enz. Inhib.*, **12**, 303-311, 1997.
 39. M.A. Kamal. Effect of malathion on kinetic parameters of acetylcholinesterase (EC 3.1.1.7) in vitro. *Biochem. Mol. Biol. Int.*, **43** (1), 89-97, 1997.
 40. M.A. Kamal. Investigation of the effect of lannate on kinetic parameters of retinal acetylcholinesterase: Slightly concave mixed type of inhibition system. *Biochem. Mol. Biol. Int.*, **43** (5), 1183-1193, 1997.
 41. M.A. Kamal, M.S. Bakkar & A.A. Al-Jafari. Estimation and correlation of IC₅₀ for the inhibition of human erythrocyte acetylcholinesterase by cis-Diamminediaquaplatinum (II). *Anticancer Res.*, **17**(6), 4483-4486, 1997.
 42. M.A. Kamal. Kinetics of human erythrocyte acetylcholinesterase inhibition by cis-Diamminediaquaplatinum (II). *Anticancer Res.*, **17**, 4487-4492, 1997.
 43. A.A. Al-Jafari & M.A. Kamal. Optimization and kinetic studies of human erythrocyte membrane-bound acetylcholinesterase. *Biochem. Mol. Biol. Int.*, **38**, 577-586, 1996.
 44. M.A. Kamal & A.A. Al-Jafari. The preparation and kinetic analysis of multiple forms of human erythrocyte acetylcholinesterase. *Prep. Biochem. & Biotech.*, **26**, 105-119, 1996.
 45. M.A. Kamal & A.A. Al-Jafari. Estimation and correlation of IC₅₀ with time for the inhibition of human erythrocyte acetylcholinesterase by cisplatin. *Cell. Pharmacol.*, **3**, 45-48, 1996.
 46. A.S. Duhaiman, A.S. Alhomida, N. Rabbani, M.A. Kamal & A.A. Al-Jafari. Purification and characterization of acetylcholinesterase from desert cobra (*Walterinnesia aegyptia*) venom. *Biochimie*, **77**, 46-50, 1996.
 47. M.A. Kamal, F.H. Nasim & A.A. Al-Jafari. Investigation of the effect of anti-neoplastic drugs: cyclophosphamide, cisplatin and methotrexate on the turnover kinetics of human erythrocyte acetylcholinesterase. *Biochem. Mol. Biol. Int.*, **39**, 293-302, 1996.
 48. M.A. Kamal, F.H. Nasim, & A.A. Al-Jafari. In vitro inhibition of human erythrocyte acetylcholinesterase (EC 3.1.1.7) by an antineoplastic drug methotrexate. *Mol. Cell. Biochem.*, **159**, 47-53, 1996.

49. A.A. Al-Jafari & M.A. Kamal. Investigation of the effect of tetrahydroaminoacridine on turnover kinetics of camel (*Camelus dromedarius*) retina acetylcholinesterase. *Biochem. Mol. Biol. Int.*, **39**, 917-922, 1996.
50. Al-Jafari, F. Al-Khwyter, M. A. Kamal & A.S. Alhomida. Kinetics for camel (*Camelus dromedarius*) retina acetylcholinesterase inhibition by methotrexate in vitro. *Jpn. J. Pharmacol.*, **72**, 49-55, 1996.
51. F. Al-Khwyter, M.A. Kamal & A.A. Al-Jafari. The inhibitory effect of cyclophosphamide on camel retina acetylcholinesterase activity. *Toxicol. Lett.*, **87**, 69-76, 1996.
52. A.A. Al-Jafari, M.A. Kamal, A.S. Duhaiman & A.S. Alhomida. Kinetics of the inhibition of acetylcholinesterase from desert cobra (*Walterinnesia aegyptia*) venom by local anesthetics: procaine & tetracaine. *J. Enz. Inhib.*, **11**, 123-134, 1996.
53. M.A. Kamal. Characterization of human erythrocyte membrane-bound acetylcholinesterase inhibition by cisplatin at reversible phase. *Anticancer Res.*, **16** (6B), 3725-3730, 1996.
54. A.A. Al-Jafari, M.A. Kamal., A.S. Duhaiman & A.S. Alhomida. Acetylcholinesterase from desert cobra (*Walterinnesia aegyptia*) venom: Optimization and Kinetics study. *Mol. Cell. Biochem.*, **151**, 21-26, 1995.
55. A.A. Al-Jafari, A.S. Duhaiman & M.A. Kamal. Inhibition of human acetylcholinesterase by cyclophosphamide. *Toxicology*, **96**, 1-6, 1995.
56. A.A. Al-Jafari, M.A. Kamal & A.S. Duhaiman. The mode of inhibition of human erythrocyte membrane-bound acetylcholinesterase by cisplatin in vitro. *J. Enz. Inhibit.*, **8**, 281-289, 1995.
57. Matin, M.A. Kamal & F.H. Nasim. Energetic studies of acetylcholinesterase inhibition by 2-(diethylamino)-N-(2, 6-dimethylphenyl) acetamide. *Pak. J. Pharm.*, **6**, 73-83, 1994.
58. A.A. Al-Jafari & M.A. Kamal. The preparation and Kinetic properties of multiple forms of chicken brain acetylcholinesterase. *Cell. Biochem. Funct.*, **12**, 209-216, 1994.